Lenalidomide may reduce risk of progression from SMM to MMMay 16, 2019Multiple MyelomaLymphoma & Plasma Cell DisordersHematology
CAR T-cell therapy bb2121 performs well in phase 1 trial of refractory multiple myelomaMay 1, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
ASCO, CCO issue multiple myeloma treatment guidelinesApril 4, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
FDA halts enrollment in trial of venetoclax for multiple myelomaMarch 22, 2019Multiple MyelomaHematology
Oral triplet deemed effective in relapsed/refractory myelomaMarch 13, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Myeloma risk score has treatment-planning potentialMarch 12, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Myeloma therapies raise cardiovascular risksMarch 1, 2019Multiple MyelomaHematologyLymphoma & Plasma Cell DisordersOncology
Similar results for once- or twice-weekly carfilzomib in MMFebruary 23, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
10 Important VA Studies You Might Have Missed at ASHDecember 14, 2018Lymphoma & Plasma Cell DisordersMultiple Myeloma
TOURMALINE-MM3: Ixazomib improves PFS after myeloma transplantDecember 2, 2018Multiple MyelomaLymphoma & Plasma Cell Disorders
Will quad therapy become the new standard in myeloma?October 2, 2018Multiple MyelomaLymphoma & Plasma Cell Disorders
STORM trial shows response in penta-refractory myelomaSeptember 16, 2018Multiple MyelomaLymphoma & Plasma Cell DisordersOncologyHematology
Occurrence of Skeletal-Related Events in Multiple Myeloma and Prostate Cancer Patients Receiving Standard Versus Extended-Interval Zoledronic Acid September 12, 2018Multiple MyelomaProstate Cancer
